Under construction – not a live service
Sign in
Not yet taking people in FranceNo phase

Cabotegravir and Lenacapavir Long-Acting Treatment in People With HIV-1

Follows adults with HIV-1 using long-acting cabotegravir and lenacapavir to check results and safety.

Plain-language title generated from the registry record
Registry title: CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

Key facts

Where
Argenteuil, Bordeaux, Garches, Levallois-Perret, Nantes, Nice, Paris, and Tourcoing, FranceSee the 13 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with HIV-1 who already take, or are about to start, the long-acting combination of cabotegravir and lenacapavir.

Age
18 years or older
Sex
All sexes can join.
Disease stage
HIV-1 infection.
Earlier treatment
Either started cabotegravir with lenacapavir between July 2024 and the one-year follow-up, or about to start this combination after a medical decision.

Main reasons for not taking part

  • Objects to the use of their follow-up data

This trial only enrols participants living with HIV. The registry sentence this rests on: HIV-1 infection

Read by machine on 12 November 2026.

Where in France

  • Victor Dupuy HospitalArgenteuil, FranceContact: Fabienne CABYNo longer taking part
  • Pellegrin HospitalBordeaux, FranceContact: Didier NEAUNo longer taking part
  • Saint André HospitalBordeaux, FranceContact: Fabrice BONNETNo longer taking part
  • Raymond-Poincare HospitalGarches, FranceContact: Pierre de TruchisNo longer taking part
  • Franco-British Hospital (Fbh)Levallois-Perret, FranceContact: Gilles FORCENo longer taking part
  • Hotel Dieu HospitalNantes, FranceContact: Colin DESCHANVRESNo longer taking part
  • Archet 1HospitalNice, FranceContact: David CHIRIONo longer taking part
  • Bichat-Claude Bernard HospitalParis, FranceContact: Roland LANDMANNo longer taking part
  • Hôtel Dieu HospitalParis, FranceContact: Romain PALICHNo longer taking part
  • Necker HospitalParis, FranceContact: Claudine DUVIVIERNo longer taking part
  • Pitié Salpêtrière HospitalParis, FranceContact: Valérie POURCHERNo longer taking part
  • Saint-Antoine HospitalParis, FranceContact: karine LACOMBENo longer taking part
  • Tourcoing HospitalTourcoing, FranceContact: Nathalie VIGETNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Trial code
NCT07402044
Record updated
27 March 2026
Original description
The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.Read full original descriptionShow less

CAbotégravir LENacapavir DUal Long Acting). Immuno-virological Monitoring and Safety Assessment of HIV-1 Infected Patients Receiving a Long-Acting Antiretroviral Combination of Cabotegravir and Lenacapavir

The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.

Exclusion: Participants' objection to the use of follow-up data.

Age ≥18 years; HIV-1 infection; Patients who started taking cabotegravir combined with lenacapavir between July 2024 and the one-year follow-up, or who are due to start taking the CAB/LEN combination; Patients who are due to start the CAB/LEN combination following a medical decision.

ClinicalTrials.gov NCT07402044